Clinical Trial Update: A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

View source ↗

Summary

A clinical trial update indicates completion of a study evaluating tafamidis 61 mg in people with transthyretin amyloid cardiomyopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Vyndamax (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: Transthyretin Amyloid Cardiomyopathy | Status: COMPLETED